MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008

Tuesday, April 29, 2008 General News J E 4
VALENCIA, Calif., April 28 MannKind Corporation(Nasdaq: MNKD) will release its 2008 first quarter financial results onMonday, May 5, 2008 at 4:00 p.m. EDT.

Management of the Company will host a conference call to discuss the firstquarter financial results, clinical progress and other Company developments at5:00 p.m. EDT on Monday, May 5, 2008. Presenting from the Company will be itsChairman and Chief Executive Officer, Alfred Mann; President and ChiefOperating Officer, Hakan Edstrom; Corporate Vice President and Chief FinancialOfficer, Matthew Pfeffer and Corporate Vice President and Chief ScientificOfficer, Peter Richardson.

To participate in the live call by telephone, please dial (800) 857-0373or (210) 839-8507. Those interested in listening to the conference call livevia the Internet may do so by visiting the Company's website at

A telephone replay of the call will be accessible for approximatelyfourteen days following completion of the call by dialing (866) 457-6651 or(203) 369-1300. A replay will also be available on MannKind's website forfourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, developmentand commercialization of therapeutic products for diseases such as diabetesand cancer. Its lead product, the Technosphere(R) Insulin System, is currentlyin Phase 3 clinical trials in the United States, Europe and Latin America tostudy its safety and efficacy in the treatment of diabetes. For moreinformation on MannKind Corporation and its technology, visit

SOURCE MannKind Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
MannKind to Present at the Morgan Stanley Healthca...
Long-Term Financial Benefits of Drug-Eluting Stent...